Atlas Trials

The Study of Vidicizumab Combined With Tirelizumab in the Treatment of Breast Cancer With Low HER2 Expression

Clinical trial NCT05861635 · UNKNOWN

Trial details

NCT number
NCT05861635
Sponsor
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Status
UNKNOWN
Phase
Phase 4
Study type
INTERVENTIONAL
Breast CancerNeoadjuvant Therapy
Start date
2023-02-01
Primary completion
2025-02-01
Enrollment
42

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.